Owlet (OWLT) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
16 Dec, 2025Company overview and business model
Provides digital health infant monitoring solutions, including FDA-authorized pediatric wearables and integrated HD cameras for real-time health and sleep insights to parents worldwide.
Over 2 million parents globally have used the platform, contributing to a large dataset of infant health and sleep data.
Focuses on bridging the healthcare gap between hospital and home with software and digital data solutions.
Risk factors and disclosures
Faces risks from limited operating history, ongoing operating losses, and potential inability to achieve profitability.
Subject to regulatory risks, including requirements for marketing authorizations for medical devices and reliance on single manufacturers for key products.
Exposed to risks from IT system failures, cybersecurity threats, product liability, and international operations.
Material weaknesses in internal controls over financial reporting have been identified.
May need to raise additional capital in the future, and failure to meet NYSE listing requirements could result in delisting.
Market opportunity and competitive landscape
Aims to deliver real-time, medical-grade health insights for at-home infant care, addressing a global market of parents and caregivers.
Latest events from Owlet
- Up to 9.6 million shares registered for resale by major holders; no proceeds to the company.OWLT
Registration Filing10 Mar 2026 - Record revenue, margin, and subscriber growth; strong 2026 outlook with global and AI expansion.OWLT
Q4 20255 Mar 2026 - Q1 revenue up 43% with record margin, breakeven EBITDA, and raised guidance amid ongoing risks.OWLT
Q1 20253 Feb 2026 - Dual FDA clearances and strong retail momentum position the company for rapid growth and margin expansion.OWLT
TD Cowen’s 8th Annual Future of the Consumer Conference1 Feb 2026 - Q2 revenue up 58% to $20.7M, gross margin 50%, but going concern risk remains.OWLT
Q2 20241 Feb 2026 - Q3 revenue up 141% to $22.1M, record margin, positive EBITDA, but liquidity risks remain.OWLT
Q3 202414 Jan 2026 - Record 2024 results, new FDA-cleared products, and margin gains set up for 2025 profitability.OWLT
Q4 202426 Dec 2025 - Resale registration for 750,000 shares tied to a term loan, with no proceeds to the company.OWLT
Registration Filing16 Dec 2025 - Registration enables major investors to resell 5.3M shares, with no proceeds to the company.OWLT
Registration Filing16 Dec 2025